Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Favret

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Breast Journal|May 12, 2001
Multidisciplinary Management of Locally Advanced Breast CancerRobert W. Carlson, Anne M. Favret
Hematology/Oncology Clinics of North America|May 22, 2007
HER2-positive advanced breast cancerNicholas J Robert, Anne M Favret
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2015
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology PracticesNeelima Denduluri, Debra A Patt, Yunfei Wang, et al.
Breast Cancer Research and Treatment|October 24, 2017
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trialGabe S Sonke, Lowell L Hart, Mario Campone, et al.
The Lancet. Oncology|September 7, 2013
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 studyStephen E Jones, Rufus Collea, Devchand Paul, et al.
The New England Journal of Medicine|October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Breast Journal|May 12, 2001
Multidisciplinary Management of Locally Advanced Breast CancerRobert W. Carlson, Anne M. Favret
Hematology/Oncology Clinics of North America|May 22, 2007
HER2-positive advanced breast cancerNicholas J Robert, Anne M Favret
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2015
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology PracticesNeelima Denduluri, Debra A Patt, Yunfei Wang, et al.
Breast Cancer Research and Treatment|October 24, 2017
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trialGabe S Sonke, Lowell L Hart, Mario Campone, et al.
The Lancet. Oncology|September 7, 2013
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 studyStephen E Jones, Rufus Collea, Devchand Paul, et al.
The New England Journal of Medicine|October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
Pageof 1